Heidi J Gray

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes
    Heidi J Gray
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Obstet Gynecol Int 2010:743794. 2010
  2. ncbi request reprint Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Natl Compr Canc Netw 6:47-52. 2008
  3. doi request reprint Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
    Gynecol Oncol 116:340-4. 2010
  4. pmc Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 123:461-6. 2011
  5. pmc Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly
    Melissa M Thrall
    Department of Obstetrics, University of Washington School of Medicine, University of Washington, Seattle, Washington 98195 6460, USA
    Obstet Gynecol 118:537-47. 2011
  6. doi request reprint Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study
    Kathryn F McGonigle
    Women s Cancer Care of Seattle, Seattle, Washington 98133, USA
    Cancer 117:3731-40. 2011
  7. ncbi request reprint Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas
    Vijaya Galic
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
    Genes Chromosomes Cancer 46:239-47. 2007
  8. doi request reprint Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
    Gynecol Oncol 118:43-6. 2010
  9. ncbi request reprint Glassy cell carcinoma of the cervix revisited
    Heidi J Gray
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 85:274-7. 2002
  10. doi request reprint Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
    Chirag A Shah
    University of Washington Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Seattle, Washington 98195, USA
    Gynecol Oncol 109:215-9. 2008

Collaborators

Detail Information

Publications22

  1. pmc The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes
    Heidi J Gray
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Obstet Gynecol Int 2010:743794. 2010
    ..168). Overall survival in the abandoned group was 73% versus 80% in the completed group (P = .772). Conclusion. The practice of abandoning a planned radical hysterectomy for unexpected metastatic disease may not worsen the outcome...
  2. ncbi request reprint Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98195, USA
    J Natl Compr Canc Netw 6:47-52. 2008
    ..In select patients with stage IB2 disease with bulky tumors undergoing primary chemoradiation, adjuvant hysterectomy may provide benefit after treatment...
  3. doi request reprint Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
    Heidi J Gray
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, WA 98195, USA
    Gynecol Oncol 116:340-4. 2010
    ..We hypothesized that women treated with alternative IP chemotherapy strategies may have less toxicity and improved compliance...
  4. pmc Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 123:461-6. 2011
    ..While NAC may facilitate and simplify complete cytoreduction and reduce the risk of surgery, the delay of surgery related to NAC needs to be balanced against any potential benefit...
  5. pmc Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly
    Melissa M Thrall
    Department of Obstetrics, University of Washington School of Medicine, University of Washington, Seattle, Washington 98195 6460, USA
    Obstet Gynecol 118:537-47. 2011
    ..To identify factors associated with increased 30-day mortality after advanced ovarian cancer debulking among elderly women...
  6. doi request reprint Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study
    Kathryn F McGonigle
    Women s Cancer Care of Seattle, Seattle, Washington 98133, USA
    Cancer 117:3731-40. 2011
    ..A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC)...
  7. ncbi request reprint Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas
    Vijaya Galic
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA
    Genes Chromosomes Cancer 46:239-47. 2007
    ..04). Somatic mutation or deletion was equally common for either codon 72 allele. Age of diagnosis was not influenced by codon 72 but showed a trend for younger age in women with somatic TP53 mutations and the MDM2 G/G genotype...
  8. doi request reprint Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
    Gynecol Oncol 118:43-6. 2010
    ..Recent studies have suggested inferior outcomes for elderly women with ovarian cancer. Our goal was to evaluate neoadjuvant chemotherapy versus primary cytoreduction in elderly women...
  9. ncbi request reprint Glassy cell carcinoma of the cervix revisited
    Heidi J Gray
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 85:274-7. 2002
    ..An earlier series from our institution supported a grim prognostic outlook, demonstrating a survival rate of only 55% in women with stage I disease. We present a comparison of a contemporary series of patients with GCC...
  10. doi request reprint Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer
    Chirag A Shah
    University of Washington Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Seattle, Washington 98195, USA
    Gynecol Oncol 109:215-9. 2008
    ..Forty percent of women with ovarian cancer have circulating free tumor DNA. We sought to determine if the tumor immune infiltrate varied based on tumor p53 mutation status or presence of circulating tumor DNA...
  11. doi request reprint FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gynecol Oncol 120:296-9. 2011
    ..To characterize clinical features of vulvar Paget's disease, and examine the quantity of immunosuppressive regulatory T-cells in vulvar Paget's tissue...
  12. doi request reprint Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma
    Christopher B Morse
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, United States Electronic address
    Gynecol Oncol 143:389-392. 2016
    ....
  13. pmc Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers
    Minh D Dao
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195 6460, USA
    Gynecol Oncol 130:295-9. 2013
    ..To evaluate patterns of recurrence for ovarian, fallopian tube, and primary peritoneal cancer patients undergoing extended treatment with bevacizumab (BEV)...
  14. pmc Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma
    Ruchi Garg
    Division of Gynecologic Oncology, University of Washington Medical Center, Seattle 98195, USA
    Gynecol Oncol 103:793-6. 2006
    ..The IL6 -174 promoter polymorphism impacts serum cytokine levels through transcriptional regulation. The objective of our study was to determine if -174 IL6 genotype influences survival in ovarian cancer...
  15. doi request reprint Pelvic exenteration in the age of modern chemoradiation
    Kate A McLean
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 121:131-4. 2011
    ..To examine outcomes after pelvic exenteration in women treated with modern chemoradiation and surgical techniques...
  16. doi request reprint An evaluation of cervical cancer in women age sixty and over
    Katrina V Fox
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Gynecol Oncol 109:53-8. 2008
    ..To assess prior cervical cancer screening, stage at time of diagnosis and outcome in women sixty years of age and over with cervical cancer...
  17. ncbi request reprint Surgery for ovarian cancer: rationale and guidelines
    Benjamin E Greer
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, Washington 98195 6460, USA
    J Natl Compr Canc Netw 2:561-8. 2004
    ....
  18. doi request reprint Route of hysterectomy and surgical outcomes from a statewide gynecologic oncology population: is there a role for vaginal hysterectomy?
    Tiffany L Beck
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
    Am J Obstet Gynecol 214:348.e1-9. 2016
    ..It is not known if advantages of VH for benign indications apply to women with gynecologic cancer...
  19. pmc Trends in treatment of advanced epithelial ovarian cancer in the Medicare population
    Melissa M Thrall
    Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Gynecol Oncol 122:100-6. 2011
    ..This study evaluated patterns of care, frequency of completion of recommended therapy and factors associated with sequencing of therapy...
  20. ncbi request reprint Delayed hemorrhage after cervical conization unmasking severe factor XI deficiency
    Sarah H Kim
    Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Obstet Gynecol 104:1189-92. 2004
    ..Factor XI deficiency, a rare bleeding disorder found most commonly in patients of Ashkenazi Jewish background, may be present in patients with a history of abnormal bleeding after elective surgery...
  21. doi request reprint Ovarian cancer outcomes: Predictors of early death
    Renata R Urban
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States Electronic address
    Gynecol Oncol 140:474-80. 2016
    ..To describe the outcomes and mortality in advanced ovarian cancer patients in a population-based cohort in the 90 days after diagnosis...
  22. ncbi request reprint Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma
    Thomas S Dardarian
    Department of Obstetrics and Gynecology, Pennsylvania Hospital, Philadelphia, PA 19104, USA
    Gynecol Oncol 101:140-2. 2006
    ..To compare short- and long-term morbidity associated with saphenous vein sparing versus ligation during inguinal lymphadenectomy for vulvar carcinoma...